Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Exclusion Criteria

• •Subject has received treatment with the following hypomethylating agent and/or chemo therapeutic agent for for an antecedent hematologic disorder (AHD) (Subjects may have been treated with other agents for AHD i.e., Myelodysplastic syndrome \[MDS\])
• •Subject has history of Myeloproliferative Neoplasm (MPN).
• •Subject has favorable risk cytogenetics as categorized by the National Comprehensive Cancer Network Guidelines Version 2, 2014 for AML.
• •Subject has t(8;21), inv(16), t(16;16) or t(15;17) karyotype abnormalities.
• •Subject has acute promyelocytic leukemia.
• •Subject has known active central nervous system involvement with AML.
• •Subject has received a strong and/or moderate CYP3A inducer within 7 days prior to the initiation of study treatment.
• •Subject has a history of other malignancies prior to study entry, with the exception of:
• •* Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
• •* Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
• •* Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
• •Subject has a white blood cell count \> 25 × 10\^9/L. Note: Hydroxyurea is permitted to meet this criterion.